BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents

Blood

Volumn 86, Issue 3, 1995, Pages 1148-1158

  Bedi, Atul ^a   Barber, James P ^a   Bedi, Gauri C ^a   El Deiry, Wafik S ^a   Sidransky, David ^a   Vala, Milada S ^a   Akhtar, Adil J ^a   Hilton, John ^a   Jones, Richard J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DAUNORUBICIN; ETOPOSIDE; PROTEIN P21; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE PHASE; CHROMOSOME 22; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0029131231     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v86.3.1148.1148     Document Type: Article

References (58)

1. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290, 1973
2. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
3. Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte ON, Baltimore D: The chronic myelogenous leukemia - Specific P210 protein is the product of the bcr-abl hybrid gene. Science 233:212, 1986
4. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93, 1984
5. Gishizky ML, Witte ON: Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256:836, 1992
6. bcr-abl gene of the Philadelphia chromosome. Science 247:824, 1990
7. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: A concise update. Blood 82:691, 1993
8. Wagner JE, Zahurak M, Piantadosi S, Geller RB, Vogelsang GB, Wingard JR, Saral R, Griffin C, Shah N, Zehnbauer BA, Ambinder R, Burns W, Jones R, May WS, Rowley S, Yeager A, Santos GW: Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits. J Clin Oncol 10:779, 1992
9. Chabner BA, Myers CE: Clinical pharmacology of cancer chemotherapy, in DeVita VTJ, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, p 349
10. Hartwell LH, Weinert TA: Checkpoints: Controls that ensure the order of cell cycle events. Science 246:629, 1989
11. Dulic V, Kaufmann WK, Wilson SJ. Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013, 1994
12. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
13. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge S: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
14. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JE, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169, 1994
15. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491, 1992
16. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304, 1991
17. Lu X, Lane DP: Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes? Cell 75:765, 1993
18. Lowe SW, Ruley HE, Jacks T, Housman D: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
19. Clark AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849, 1993
20. Lowe SW, Schmitt EM, Smith SW, Osborne B, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
21. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345, 1991
22. Williams GT: Programmed cell death: Apoptosis and oncogenesis. Cell 65:1097, 1991
23. Williams GT, Smith CA: Molecular regulation of apoptosis: Genetic controls on cell death. Cell 74:777, 1993
24. Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, Canaani E: p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88:6293, 1991
25. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ: Alterations of the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86:6783, 1989
26. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038, 1994
27. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
28. Palacios R, Steinmetz M: IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41:727, 1985
29. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D: Growth of factor-dependent hemopoietic precursor cell lines. J Exp Med 152:1036, 1980
30. bcr-abl protein. Proc Natl Acad Sci USA 85:9312, 1988
31. Hariharan IK, Adams JM, Cory S: bcr-abl oncogene renders myeloid cell line factor independent: Potential autocrine mechanisms in chronic myeloid leukemia. Oncogene Res 3:387, 1988
32. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562, 1991
33. Hilton J: Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. Biochem Pharmacol 33:1867, 1984
34. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
35. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795, 1992
36. Gorczyca W, Gong J, Darzynkiewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53:1945, 1993
37. Collins MKL, Marvel J, Malde P, Lopez-Rivas A: Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 176:1043, 1992
38. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344:503, 1990
39. cdc2 cyclin B complex formation. Proc Natl Acad Sci USA 88:6843, 1991
40. Al-Khodairy F, Carr AM: DNA repair mutants defining G2 checkpoint pathways in Schizosaccharomyces pome. EMBO J 11:1343, 1992
41. Sokal JE, Leong SS, Gomez GA: Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 59:197, 1987
42. Spiro TE, Mattelaer M-A, Efira A, Stryckmans P: Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J Natl Cancer Inst 66:1053, 1981
43. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR: Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76, 1990
44. Bedi A, Griffin CA, Barber JP, Vala MS, Hawkins AL, Sharkis SJ, Zehnbauer BA, Jones RJ: Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res 54:5535, 1994
45. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539, 1994
46. Murray A: The cell cycle as a cdc2 cycle. Nature 341:14, 1989
47. +, a gene encoding a protein kinase homolog. Cell 45:559, 1987
48. Weinert T, Hartwell L: The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317, 1988
49. Barbet NC, Carr AM: Fission yeast weel protein kinase is not required for DNA-damage dependent mitotic arrest. Nature 364:824, 1993
50. cdc2 activation required for apoptosis. Science 263:1143, 1994
51. Shimizu T, O'Connor PM, Kohn KW, Pommier Y: Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55:228, 1995
52. cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res 50:3767, 1990
53. McKenna WG, Iliakis G, Weiss MC, Bernhard EJ, Muschel RJ: Increased G2 delay in radiation-resistant cells obtained by transformation of primary rate embryo cells with the oncogenes H-ras and v-myc. Radiat Res 125:283, 1991
54. Nowell PC: The clonal evolution of tumor cell populations. Science 194:23, 1976
55. Murray AW: Creative blocks: Cell-cycle checkpoints and feedback controls. Nature 359:599, 1992
56. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543, 1993
57. Livingstone L, White A, Sprouse J, Livanos E, Jacks T, Tisty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70:925, 1992
58. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937, 1992